

## NIGERIA – Pentavalent vaccine support

This decision letter sets out the programme terms of a programme.

| <b>1. Country:</b> Nigeria   |   |                |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
|--|---|----------------|--------------------|--------------------------------------|-------------------------|------------------------------|-----------------------|-----------------|------------|------------------------|--|---------|-----------------------|------------------------------|----------------|
| <b>2. Grant number:</b> 16-NGA-04c-X   |   |                |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| <b>3. Date of decision letter:</b> 20 November 2015  |   |                |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| <b>4. Date of the Partnership Framework Agreement:</b> 9 January 2014  |   |                |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| <b>5. Programme title:</b> New vaccine support (NVS), Pentavalent Routine  |   |                |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| <b>6. Vaccine type:</b> Pentavalent  |   |                |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| <b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 10 dose(s) per vial, LIQUID   |   |                |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| <b>8. Programme duration<sup>1</sup>:</b> 2012 - 2016  |   |                |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| <b>9. Programme budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <table border="1" style="margin: 10px auto; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 20%;"></th> <th style="width: 25%;">2012-2015</th> <th style="width: 25%;">2016</th> <th style="width: 30%;">Total<sup>2</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: left;">Programme budget (US\$)</td> <td>US\$102,012,982<sup>3</sup></td> <td>US\$38,333,000</td> <td>US\$140,345,982</td> </tr> </tbody> </table>   |   | 2012-2015      | 2016               | Total <sup>2</sup>                   | Programme budget (US\$) | US\$102,012,982 <sup>3</sup> | US\$38,333,000        | US\$140,345,982 |            |                        |  |         |                       |                              |                |
|  | 2012-2015   | 2016           | Total <sup>2</sup> |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| Programme budget (US\$)  | US\$102,012,982 <sup>3</sup>                                  | US\$38,333,000 | US\$140,345,982    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| <b>10. Vaccine introduction grant (in US\$):</b> . Not applicable.   |   |                |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| <b>11. Indicative annual amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup> <table border="1" style="margin: 10px auto; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 45%;">Type of supplies to be purchased with Gavi funds in each year</th> <th style="width: 25%;">2012-2015</th> <th style="width: 30%;">2016</th> </tr> </thead> <tbody> <tr> <td>Number of Pentavalent vaccines doses</td> <td></td> <td>20,412,500</td> </tr> <tr> <td>Number of AD syringes</td> <td></td> <td>16,520,100</td> </tr> <tr> <td>Number of safety boxes</td> <td></td> <td>181,750</td> </tr> <tr> <td>Annual amounts (US\$)</td> <td>US\$102,012,982<sup>5</sup></td> <td>US\$38,333,000</td> </tr> </tbody> </table> | Type of supplies to be purchased with Gavi funds in each year | 2012-2015      | 2016               | Number of Pentavalent vaccines doses |                         | 20,412,500                   | Number of AD syringes |                 | 16,520,100 | Number of safety boxes |  | 181,750 | Annual amounts (US\$) | US\$102,012,982 <sup>5</sup> | US\$38,333,000 |
| Type of supplies to be purchased with Gavi funds in each year  | 2012-2015   | 2016           |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| Number of Pentavalent vaccines doses   |   | 20,412,500     |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| Number of AD syringes  |   | 16,520,100     |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| Number of safety boxes   |   | 181,750        |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| Annual amounts (US\$)  | US\$102,012,982 <sup>5</sup>                                  | US\$38,333,000 |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| <b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.  |   |                |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |
| <b>13. Self-procurement:</b> Not applicable.   |   |                |                    |                                      |                         |                              |                       |                 |            |                        |  |         |                       |                              |                |

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

| <p><b>14. Co-financing obligations:</b> Reference code: 16-NGA-04c-X-C</p> <p>According to the co-financing policy, the Country falls within the group Preparatory transition.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>  |                               |                               |           |   |             |   |                               |
|--|-------------------------------|-------------------------------|-----------|---|-------------|---|-------------------------------|
| Type of supplies to be purchased with Country funds in each year   | 2016                          |                               |           |   |             |   |                               |
| Number of vaccine doses  | 6,063,000                     |                               |           |   |             |   |                               |
| Number of AD syringes  | 4,906,400                     |                               |           |   |             |   |                               |
| Number of safety boxes   | 53,975                        |                               |           |   |             |   |                               |
| Value of vaccine doses (US\$)  | US\$10,894,788                |                               |           |   |             |   |                               |
| Total co-financing payments (US\$) (including freight)   | US\$11,384,500                |                               |           |   |             |   |                               |
| <p><b>15. Operational support for campaigns:</b> Not applicable</p>  |                               |                               |           |   |             |   |                               |
| <p><b>16. Additional reporting requirements:</b> The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.</p> <table border="1"> <thead> <tr> <th style="text-align: center;">Reports and other information</th> <th style="text-align: center;">Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td style="text-align: center;">15 May 2016</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td style="text-align: center;">To be agreed with Secretariat</td> </tr> </tbody> </table> |                               | Reports and other information | Due dates | To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | 15 May 2016 | In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Secretariat |
| Reports and other information  | Due dates                     |                               |           |   |             |   |                               |
| To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.  | 15 May 2016                   |                               |           |   |             |   |                               |
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.  | To be agreed with Secretariat |                               |           |   |             |   |                               |
| <p><b>17. Financial clarifications:</b> Not applicable.</p>  |                               |                               |           |   |             |   |                               |
| <p><b>18. Other conditions:</b> Not applicable.</p>  |                               |                               |           |   |             |   |                               |

On behalf of Gavi



Hind Khatib-Othman  
 Managing Director, Country Programmes

20 November 2015

## NIGERIA – Pneumococcal vaccine support

This decision letter sets out the programme terms of a programme.

|   |                             |                 |                    |
|---|-----------------------------|-----------------|--------------------|
| <b>1. Country:</b> Nigeria  |                             |                 |                    |
| <b>2. Grant number:</b> 16-NGA-12b-X  |                             |                 |                    |
| <b>3. Date of decision letter:</b> 20 November 2015   |                             |                 |                    |
| <b>4. Date of the Partnership Framework Agreement:</b> 9 January 2014   |                             |                 |                    |
| <b>5. Programme title:</b> New vaccine support (NVS), Pneumococcal Routine  |                             |                 |                    |
| <b>6. Vaccine type:</b> Pneumococcal  |                             |                 |                    |
| <b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV10), 2 doses per vial, LIQUID             |                             |                 |                    |
| <b>8. Programme duration<sup>1</sup>:</b> 2014 - 2016   |                             |                 |                    |
| <b>9. Programme budget (indicative):</b> (subject to the terms of the partnership framework agreement, if applicable)           |                             |                 |                    |
|   | 2014-2015                   | 2016            | Total <sup>2</sup> |
| Programme budget (US\$)   | US\$56,571,500 <sup>3</sup> | US\$106,397,000 | US\$162,968,500    |
| <b>10. Vaccine introduction grant (in US\$):</b> Not applicable.  |                             |                 |                    |
| <b>11. Indicative annual amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup> |                             |                 |                    |
| Type of supplies to be purchased with Gavi funds in each year   | 2014-2015                   | 2016            |                    |
| Number of Pneumococcal vaccines doses   |                             | 21,034,800      |                    |
| Number of AD syringes   |                             | 21,043,200      |                    |
| Number of safety boxes  |                             | 231,500         |                    |
| Annual amounts (US\$)   | US\$56,571,500 <sup>5</sup> | US\$106,397,000 |                    |
| <b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.                 |                             |                 |                    |
| <b>13. Self-procurement:</b> Not applicable.  |                             |                 |                    |

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations:** Reference code: 16-NGA-12b-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

|  |                |
|--|----------------|
| Type of supplies to be purchased with Country funds in each year | 2016           |
| Number of vaccine doses  | 4,967,600      |
| Number of AD syringes  | 4,969,200      |
| Number of safety boxes   | 54,675         |
| Value of vaccine doses (US\$)                                    | US\$16,757,573 |
| Total co-financing payments (US\$) (including freight)           | US\$17,162,000 |

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

| Reports and other information   | Due dates                     |
|---|-------------------------------|
| To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | 15 May 2016                   |
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.   | To be agreed with Secretariat |

**17. Financial clarifications:** Not applicable.

**18. Other conditions:** Not applicable.

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes

20 November 2015

## NIGERIA - Yellow Fever vaccine campaign support

This decision letter sets out the programme terms of a programme.

|  |                             |                |                    |
|--|-----------------------------|----------------|--------------------|
| <b>1. Country:</b> Nigeria   |                             |                |                    |
| <b>2. Grant number:</b> 1316-NGA-06q-X / 1316-NGA-21a-Y  |                             |                |                    |
| <b>3. Date of decision letter:</b> 20 November 2015  |                             |                |                    |
| <b>4. Date of the partnership framework agreement:</b> 9 January 2014  |                             |                |                    |
| <b>5. Programme title:</b> NVS, Yellow Fever Campaign  |                             |                |                    |
| <b>6. Vaccine type:</b> Yellow Fever   |                             |                |                    |
| <b>7. Requested product presentation and formulation of vaccine:</b> Yellow Fever, 10 dose(s) per vial, LYOPHILISED              |                             |                |                    |
| <b>8. Programme duration<sup>1</sup>:</b> 2013 - 2016  |                             |                |                    |
| <b>9. Programme budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)            |                             |                |                    |
|  | 2013-2015                   | 2016           | Total <sup>2</sup> |
| Programme budget (US\$)  | US\$11,117,819 <sup>3</sup> | US\$21,855,000 | US\$32,972,819     |
| <b>10. Vaccine introduction grant (in US\$):</b> Not applicable.   |                             |                |                    |
| <b>11. Indicative annual amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable): <sup>4</sup> |                             |                |                    |
| Type of supplies to be purchased with Gavi funds in each year  | 2013-2015                   | 2016           |                    |
| Number of Yellow Fever vaccines doses  |                             | 20,000,000     |                    |
| Number of AD syringes  |                             | 20,952,400     |                    |
| Number of re-constitution syringes   |                             | 2,200,000      |                    |
| Number of safety boxes   |                             | 254,700        |                    |
| Annual amounts (US\$)  | US\$11,117,819 <sup>5</sup> | US\$21,855,000 |                    |

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

| <b>12. Procurement agency:</b> UNICEF.  |  |                               |           |  |  |
|---|--|-------------------------------|-----------|--|--|
| <b>13. Self-procurement:</b> Not applicable   |  |                               |           |  |  |
| <b>14. Co-financing obligations: Reference code:</b> Not applicable.  |  |                               |           |  |  |
| <p><b>15. Operational support for campaigns:</b> The support for operational costs for campaign will be disbursed in cash [through WHO and UNICEF]. [The Country will need to contact the local [WHO/UNICEF] office to arrange the utilisation of GAVI funds to support the operational costs of the campaign.</p> <table border="1" data-bbox="555 618 1008 730"> <tr> <td></td> <td>2016</td> </tr> <tr> <td>Grant amount (US\$)</td> <td>US\$12,076,500</td> </tr> </table>  |  |                               | 2016      | Grant amount (US\$)  | US\$12,076,500   |
|   | 2016   |                               |           |  |  |
| Grant amount (US\$)   | US\$12,076,500   |                               |           |  |  |
| <p><b>16. Additional reporting requirements:</b> The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.</p> <table border="1" data-bbox="290 837 1337 1021"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>Technical report including coverage survey and Financial utilisation reporting should be submitted to the Gavi Secretariat within 6 months after the completion of the campaign.</td> <td>Within six months of the finalisation of the campaign.</td> </tr> </tbody> </table> |  | Reports and other information | Due dates | Technical report including coverage survey and Financial utilisation reporting should be submitted to the Gavi Secretariat within 6 months after the completion of the campaign. | Within six months of the finalisation of the campaign. |
| Reports and other information   | Due dates  |                               |           |  |  |
| Technical report including coverage survey and Financial utilisation reporting should be submitted to the Gavi Secretariat within 6 months after the completion of the campaign.  | Within six months of the finalisation of the campaign. |                               |           |  |  |
| <b>17. Financial clarifications:</b> Not applicable.  |  |                               |           |  |  |
| <b>18. Other conditions:</b> Not applicable.  |  |                               |           |  |  |

Signed by,



Hind Khatib-Othman  
Managing Director, Country Programmes

20 November 2015